Tender number 1

The tender number (sub-contract) comprises the following medicines: ATC Code: R03DX12 · Generic name: Depemokimab · Dosage form: Injection solution · Strength: 100 mg · Packaging: Syringe/Pen · Unit value: 0.548 mg · Quantity in units: 9999. Each tender number is considered an independent sub-contract and is tendered independently of the other tender numbers. A supplier can thus choose to bid on one, several, or all tender numbers, and awards are made separately for each individual tender number. A supplier can thus be awarded one, several, or all sub-contracts. Reference is made to the tender conditions, including those regarding submitting bids under the individual tender numbers. The "quantity in units" indicated above is an estimated consumption of the medicines under the tender number, but the actual consumption may deviate significantly from it. Suppliers must take this into account. This is because these are medicines for patient treatment in public hospitals, where the patient's needs must be met. The tendered medicines are also covered by one or more recommendations and/or treatment guidelines from the Medicines Council, and the consumption of the various medicines can be significantly affected by these. For a more detailed description, please refer to the tender conditions and the framework agreement. The maximum value of the sub-contract below in point 5.1.5 is calculated as a share of 100% of the estimated total value of all sub-contracts stated in point 2.1.3. This is because all the tendered medicines are covered by one or more recommendations and/or treatment guidelines from the Medicines Council, which assesses which of the tendered medicines are recommended for treatment for different patient populations, possibly such that certain medicines are considered equivalent first choices, recommended for use in a prioritized order, or similar. The Medicines Council's assessment can therefore have a significant impact on which of the tendered medicines are used within different therapy areas and patient populations, and the consumption of individual medicines can also depend on current agreed prices. This means that it is not possible to estimate during the tender which medicines will primarily be used during the term of the framework agreement, and it is possible that the use of the medicines may change significantly during the term of the framework agreements, including in particular upon approval of new indications for individual medicines, changed treatment of one or more patient populations, and similar. The determination of the maximum value of the individual sub-contracts as a share of the total estimated quantity of all sub-contracts is intended to ensure that each of the concluded framework agreements can be used for the necessary procurement. The maximum value is thus determined based on a professional assessment of the potential use of the medicines, taking into account the special circumstances regarding the use of medicines in public hospitals and the significant impact that the Medicines Council's recommendation and/or treatment guideline can have on the actual consumption of individual medicines, including significant changes in the consumption of different medicines.